These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Role of Somatostatin Analogues in Oncology. European Neuroendocrine Tumor Network (ENET). February 24-27, 2000, Innsbruck, Austria. Proceedings. Digestion; 2000; 62 Suppl 1():1-108. PubMed ID: 11001649 [No Abstract] [Full Text] [Related]
6. Nasopharyngeal carcinoid tumor: successful therapy for a tumor in a unique location. Warman M; Halperin D; Poria Y; Huszar M; Idelevich E Otolaryngol Head Neck Surg; 2009 Mar; 140(3):437-8. PubMed ID: 19248962 [No Abstract] [Full Text] [Related]
7. Octreotide. Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003 [No Abstract] [Full Text] [Related]
9. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Woltering EA; Mamikunian PM; Zietz S; Krutzik SR; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G Pancreas; 2005 Nov; 31(4):392-400. PubMed ID: 16258376 [TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964 [TBL] [Abstract][Full Text] [Related]
11. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Shen C; Shih YC; Xu Y; Yao JC Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Anthony L; Vinik AI Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761 [TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R; J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057 [TBL] [Abstract][Full Text] [Related]
14. Octreotide scanning for carcinoid tumours. Critchley M Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023 [TBL] [Abstract][Full Text] [Related]
15. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058 [TBL] [Abstract][Full Text] [Related]
16. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Shen C; Xu Y; Dasari A; Shih YC; Yao JC Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407 [TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508 [TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment. Janson ET; Oberg K Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762 [No Abstract] [Full Text] [Related]
20. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]